HYTN Innovations Inc., based in Vancouver, has secured its first export order for Good Manufacturing Practices (GMP) cannabis vape cartridges, marking a significant entry into the UK market. The company received a purchase order on June 6, 2025, for 1,000 one-gram live resin vape cartridges, which will be produced under GMP standards. Shipment is scheduled to occur before the import permit expiration date of September 6, 2025, pending export permit approval.
This development follows HYTN’s earlier collaboration with SNDL to create GMP-compliant vape cartridges, as announced in January 2025. Jason Broome, COO of HYTN, expressed enthusiasm about the demand for these products, emphasizing the company’s adherence to stringent international drug development standards. The order not only represents an opportunity for HYTN to expand its international reach but also showcases its capabilities in meeting the rigorous requirements of the pharmaceutical cannabis sector.
HYTN is focused on broadening its product line and reinforcing its position in the pharmaceutical cannabis market. The company’s dedication to quality and safety is evident in its adherence to GMP guidelines, which are crucial for ensuring that products are safe for consumer use. The successful execution of this order could pave the way for further opportunities in the global cannabis market, particularly in regulated environments.
As a pharmaceutical company, HYTN specializes in the formulation and manufacturing of products containing psychoactive and psychotropic compounds. This includes cannabinoids derived from cannabis and tryptamines from psilocybe mushrooms. By strategically identifying market opportunities, HYTN aims to become a premier provider in federally regulated markets.
The GMP guidelines that HYTN follows provide essential standards for manufacturing, testing, and quality assurance, ensuring the safety and efficacy of its products. Such compliance is mandatory in many regions, making it a vital aspect of the company’s operations.
With this initial order, HYTN is positioned to be a key player in the UK cannabis market and demonstrates its capability to supply high-quality cannabis products to international clients. The success of this venture could lead to additional orders and a stronger foothold in Europe’s growing pharmaceutical cannabis landscape.
Czech 
English 
Spanish 
German